ALK (Anaplastic lymphoma kinase)

P2, N=70, Recruiting, Innate Pharma | Trial completion date: Sep 2026 --> Jun 2027 | Trial primary completion date: Jun 2025 --> Jun 2027

P=N/A, N=305, Active, not recruiting, Shanghai Chest Hospital | Recruiting --> Active, not recruiting | Trial completion date: Mar 2026 --> Dec 2027 | Trial primary completion date: Mar 2025 --> Dec 2026

High-risk tumors were enriched for translational and ribosome biogenesis pathways, whereas low-risk tumors were enriched for adaptive immune activation programs. Cross-context transcriptomic integration identified a minimal ALK-associated three-gene signature that reproducibly predicts NB outcomes and reflects distinct underlying biological states, supporting its potential value for risk stratification and hypothesis-driven therapeutic development.

P2, N=132, Recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2030 --> Mar 2031 | Trial primary completion date: May 2026 --> May 2027

P2, N=39, Recruiting, University of Chicago | Not yet recruiting --> Recruiting

This study represents the latest investigation of resistance mechanisms to afatinib in NSCLC patients with nonclassical mutations. The mechanism of resistance to EGFR-TKI in this study was discovered different from that of patients with classical mutations.

Pathway-focused treatments for non-smokers, environmental interventions, and exposure-informed risk models are some potential future possibilities. Research, prevention, and patient treatment are improved worldwide when LCNS is framed as a unique, environmentally driven illness.

Patients who underwent surgery after induction treatment achieved clinically meaningful survival gains. Our findings support the use of neoadjuvant immunotherapy with a response-adapted surgical strategy as a promising approach for unresectable stage III NSCLC.

P2, N=34, Recruiting, Qilu Hospital of Shandong University | Not yet recruiting --> Recruiting

This case highlights the possibility that alectinib may impair postoperative wound repair. Comprehensive perioperative drug evaluation, multidisciplinary collaboration, and carefully monitored treatment interruption are recommended to maintain the balance between oncologic control and effective tissue healing.

This paper reported a case of concurrent SCLC transformation and ALK fusion occurring after Osimertinib treatment, suggesting that the two can coexist as dual drug resistance mechanisms. Re-biopsy combined with genetic testing is essential for identifying drug resistance mechanisms and guiding individualized therapy..

Despite the lack of formal evidence for alternative formulations, pharmacokinetic data suggest adequate absorption. Crushed lorlatinib administered through a nasogastric tube represents a practical and effective option for dysphagic patients with ALK-positive NSCLC requiring early target-directed therapy.